These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38654381)

  • 1. Exploration of treatment in childhood Langerhans cell histiocytosis based on inflammatory and malignant symptoms: a pilot study.
    Lin HL; Zheng QQ; Huang RL; Hu R; Liu XD; Wang JY
    Orphanet J Rare Dis; 2024 Apr; 19(1):174. PubMed ID: 38654381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
    Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
    Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
    Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
    Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
    Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
    Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
    BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment.
    Barkaoui MA; Queheille E; Aladjidi N; Plat G; Jeziorski E; Moshous D; Lambilliotte A; Kebaili K; Pacquement H; Leverger G; Mansuy L; Entz-Werlé N; Bodet D; Schneider P; Pagnier A; Lutun A; Gillibert-Yvert M; Millot F; Toutain F; Reguerre Y; Thomas C; Tazi A; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2020 Dec; 191(5):825-834. PubMed ID: 32700439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcome of pediatric patients diagnosed with Langerhans cell histiocytosis in pediatric hematology and oncology centers in Poland.
    Raciborska A; Bilska K; Węcławek-Tompol J; Gryniewicz-Kwiatkowska O; Hnatko-Kołacz M; Stefanowicz J; Pieczonka A; Jankowska K; Pierelejewski F; Ociepa T; Sobol-Milejska G; Muszyńska-Rosłan K; Michoń O; Badowska W; Radwańska M; Drabko K
    BMC Cancer; 2020 Sep; 20(1):874. PubMed ID: 32917181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of clinical, iconographical and pathological characteristics, prognosis and treatment methods for 35 cases of Langerhans cell histiocytosis].
    Yang H; Han XP; Li BJ; Sun L; Zhu HY; Li F; Wang QS; Huang WR; Bo J; Zhao Y; Li HH; Wang SH; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1109-14. PubMed ID: 25130838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Langerhans cell histiocytosis of skull: a retrospective study of 18 cases.
    Zhang XH; Zhang J; Chen ZH; Sai K; Chen YS; Wang J; Ke C; Guo CC; Chen ZP; Mou YG
    Ann Palliat Med; 2017 Apr; 6(2):159-164. PubMed ID: 28061539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
    Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
    Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.